Pfizer-BioNTech Vaccine (BNT162b2)

Status
To Patients
Condition
COVID-19
Intervention Type
Intramuscular (IM) Injection
Funder Type
Industry

Drug Detail

BNT162b2 is an mRNA-based vaccine program against SARS-CoV-2.

More Information

On December 11, 2020, the U.S. Food and Drug Administration issued the first emergency use authorization (EUA) for a vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older.

Pfizer-BioNTech COVID-19 Vaccine

Find a Clinical Trial

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >